HUS1300055I1 - West Nile vakcina - Google Patents

West Nile vakcina

Info

Publication number
HUS1300055I1
HUS1300055I1 HUS1300055C HUS1300055C HUS1300055I1 HU S1300055 I1 HUS1300055 I1 HU S1300055I1 HU S1300055 C HUS1300055 C HU S1300055C HU S1300055 C HUS1300055 C HU S1300055C HU S1300055 I1 HUS1300055 I1 HU S1300055I1
Authority
HU
Hungary
Prior art keywords
west nile
nile vaccine
vaccine
west
nile
Prior art date
Application number
HUS1300055C
Other languages
English (en)
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of HUS1300055I1 publication Critical patent/HUS1300055I1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
HUS1300055C 2001-07-27 2013-10-04 West Nile vakcina HUS1300055I1 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30833401P 2001-07-27 2001-07-27
PCT/US2002/023447 WO2003061555A2 (en) 2001-07-27 2002-07-23 West nile vaccine
HU0401606A HU228690B1 (en) 2001-07-27 2002-07-23 West nile vaccine

Publications (1)

Publication Number Publication Date
HUS1300055I1 true HUS1300055I1 (hu) 2016-08-29

Family

ID=27613166

Family Applications (2)

Application Number Title Priority Date Filing Date
HU0401606A HU228690B1 (en) 2001-07-27 2002-07-23 West nile vaccine
HUS1300055C HUS1300055I1 (hu) 2001-07-27 2013-10-04 West Nile vakcina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HU0401606A HU228690B1 (en) 2001-07-27 2002-07-23 West nile vaccine

Country Status (25)

Country Link
US (8) US7153513B2 (hu)
EP (3) EP2283858A3 (hu)
JP (2) JP4718778B2 (hu)
KR (2) KR20040028952A (hu)
CN (2) CN1273189C (hu)
AU (1) AU2002365244B2 (hu)
BE (1) BE2014C006I2 (hu)
BR (1) BRPI0211492B1 (hu)
CA (1) CA2452545C (hu)
CY (1) CY2014010I1 (hu)
DK (1) DK1427444T3 (hu)
ES (1) ES2435095T3 (hu)
FR (1) FR14C0016I2 (hu)
HK (1) HK1066470A1 (hu)
HR (1) HRP20040195B1 (hu)
HU (2) HU228690B1 (hu)
LU (1) LU92348I2 (hu)
ME (1) ME00491B (hu)
MX (1) MXPA04000680A (hu)
NZ (3) NZ570270A (hu)
PL (2) PL220846B1 (hu)
PT (1) PT1427444E (hu)
RS (1) RS53184B (hu)
WO (1) WO2003061555A2 (hu)
ZA (1) ZA200401596B (hu)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425437B2 (en) * 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
ME00491B (me) * 2001-07-27 2011-10-10 Zoetis Services Llc Vakcina protiv bolesti zapadnog nila
WO2005024427A2 (en) * 2003-09-09 2005-03-17 Idexx Laboratories, Inc. Detection of west nile virus infection and vaccination
US7074555B2 (en) * 2004-04-28 2006-07-11 Idexx Laboratories, Inc. Detection of West Nile Virus
FR2870126B1 (fr) 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
WO2006029300A2 (en) 2004-09-09 2006-03-16 Research Development Foundation Flavivirus variants having phenotypic variation and immunogenic compositions thereof
WO2006107655A2 (en) * 2005-04-01 2006-10-12 Wyeth Use of wnv dna vaccine in combination with a conventional vaccine to overcome immunogen interference
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
EP1879921B1 (en) 2005-05-12 2011-04-27 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
WO2006122964A1 (en) * 2005-05-19 2006-11-23 Crucell Holland B.V. Methods for the production of a whole-inactivated west nile virus vaccine
EP1724338A1 (en) * 2005-05-19 2006-11-22 Crucell Holland B.V. Methods for the production of a whole-inactivated West Nile Virus vaccine
CN101222936A (zh) * 2005-06-24 2008-07-16 英特威国际有限公司 灭活的嵌合疫苗和相关的使用方法
CN101563361B (zh) * 2005-10-19 2014-01-29 佛罗里达大学研究基金公司 能够感染犬科动物的流感病毒及其用途
WO2007047728A2 (en) * 2005-10-20 2007-04-26 Wyeth Compositions and methods for the treatment of canine influenza virus disease
US7767210B2 (en) * 2005-12-14 2010-08-03 The Board Of Regents Of The University Of Oklahoma RNA virus vaccines and methods
CN103351435B (zh) 2006-06-06 2015-08-19 克鲁塞尔荷兰公司 具有杀灭葡萄球菌活性的人结合分子及其应用
MX2010005014A (es) 2007-11-06 2010-06-30 Wyeth Llc Vacuna viva avirulenta de mycoplasma hyopneumoniae con adyuvante.
US8877208B2 (en) 2008-05-23 2014-11-04 The Regents Of The University Of Michigan Multivalent nanoemulsion vaccines
CA2732035A1 (en) * 2008-07-30 2010-02-04 University Of Kentucky Research Foundation Equine disease model for herpesvirus neurologic disease and uses thereof
AU2009287449B2 (en) * 2008-08-29 2015-04-30 Boehringer Ingelheim Animal Health USA Inc. West nile virus vaccine
WO2011043962A2 (en) * 2009-10-07 2011-04-14 Wyeth Llc Compositions comprising adjuvant, macrolide and proteinaceous antigen and methods of use thereof
CA3018230A1 (en) 2011-03-14 2012-09-20 Boehringer Ingelheim Vetmedica, Inc. Equine rhinitis b vaccine
CN103045544B (zh) * 2011-10-17 2015-01-14 华中农业大学 预防西尼罗河病毒的重组假型杆状病毒Bac-G-prM/E及疫苗与应用
PL3542819T3 (pl) * 2013-05-14 2022-01-10 Zoetis Services Llc Nowe kompozycje szczepionek zawierających oligonukleotydy immunostymulujące
US20160199482A1 (en) * 2013-09-05 2016-07-14 Zoetis Services Llc Hendra and nipah virus g glycoprotein immunogenic compositions
US11033615B2 (en) 2016-05-31 2021-06-15 The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland Zika virus vaccine and methods of production
PL70842Y1 (pl) * 2017-08-25 2019-06-28 Gondek Lukasz Kuznia Mocy Urządzenie do regeneracji filtrów cząstek stałych i katalizatorów samochodowych
US20220133877A1 (en) 2019-02-27 2022-05-05 University Of Rochester Multivalent Live-attenuated Influenza Vaccine for Prevention and Control of Equine Influenza Virus (EIV) in Horses

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US308334A (en) 1884-11-18 Ladder
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
US5741696A (en) * 1992-08-07 1998-04-21 Syntro Corporation Recombinant equine herpesviruses
FR2702373B1 (fr) * 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
ES2429401T3 (es) * 1994-05-10 2013-11-14 Boehringer Ingelheim Vetmedica, Inc. Vacuna viva modificada contra el BRSV, mejorada
AU778988B2 (en) 1998-06-04 2004-12-23 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Nucleic acid vaccines for prevention of flavivirus infection
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
AU2002211524B2 (en) * 2000-10-04 2007-03-22 The Trustees Of The University Of Pennsylvania Highly expressible genes
WO2002068637A2 (en) 2000-10-20 2002-09-06 Ribozyme Pharmaceuticals, Inc. Nucleic acid-based treatment of diseases or conditions related to west nile virus infection
US20050048073A1 (en) 2001-02-28 2005-03-03 De Groot Anne S. Methods of determining west nile virus epitopes and method of using the same
CA2440593A1 (en) * 2001-03-12 2002-09-19 Yale University Compositions and methods comprising west nile virus polypeptides
FR2823222B1 (fr) * 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
US20030104008A1 (en) * 2001-04-06 2003-06-05 Loosmore Sheena May Recombinant vaccine against west nile virus
ME00491B (me) * 2001-07-27 2011-10-10 Zoetis Services Llc Vakcina protiv bolesti zapadnog nila
AU2003263853A1 (en) 2002-08-16 2004-03-03 Board Of Regents The University Of Texas System Compositions and methods related to flavivirus envelope protein domain iii antigens

Also Published As

Publication number Publication date
US20070178119A1 (en) 2007-08-02
US20070231350A1 (en) 2007-10-04
BRPI0211492B1 (pt) 2016-06-21
EP2283858A2 (en) 2011-02-16
FR14C0016I2 (fr) 2015-07-24
PL212212B1 (pl) 2012-08-31
US20070166324A1 (en) 2007-07-19
YU8004A (sh) 2006-08-17
US20030091595A1 (en) 2003-05-15
KR20040028952A (ko) 2004-04-03
US20070231349A1 (en) 2007-10-04
US7445787B2 (en) 2008-11-04
ME00491B (me) 2011-10-10
ZA200401596B (en) 2005-07-27
ES2435095T3 (es) 2013-12-18
DK1427444T3 (da) 2013-11-04
RS53184B (en) 2014-06-30
JP2005515236A (ja) 2005-05-26
NZ570270A (en) 2010-08-27
WO2003061555A2 (en) 2003-07-31
US7153513B2 (en) 2006-12-26
WO2003061555A3 (en) 2004-04-15
LU92348I9 (hu) 2019-01-02
NZ531265A (en) 2008-08-29
NZ553165A (en) 2008-09-26
PL398575A1 (pl) 2012-06-18
PL220846B1 (pl) 2016-01-29
PT1427444E (pt) 2013-11-19
KR20090053967A (ko) 2009-05-28
US7648705B2 (en) 2010-01-19
EP2283858A3 (en) 2011-03-23
HK1066470A1 (en) 2005-03-24
BR0211492A (pt) 2004-08-17
CN1935258A (zh) 2007-03-28
JP4718778B2 (ja) 2011-07-06
BE2014C006I2 (hu) 2021-02-04
LU92348I2 (fr) 2014-09-22
CA2452545A1 (en) 2003-07-31
HUP0401606A3 (en) 2005-02-28
EP1427444A4 (en) 2008-01-02
JP2011057692A (ja) 2011-03-24
AU2002365244B2 (en) 2007-12-06
HU228690B1 (en) 2013-05-28
MXPA04000680A (es) 2004-04-05
CN1535157A (zh) 2004-10-06
CA2452545C (en) 2015-06-09
US7648706B2 (en) 2010-01-19
HRP20040195B1 (hr) 2014-07-18
EP2281572A1 (en) 2011-02-09
US20070166326A1 (en) 2007-07-19
EP1427444A2 (en) 2004-06-16
EP1427444B1 (en) 2013-08-21
CY2014010I1 (el) 2020-05-29
PL368535A1 (en) 2005-04-04
US20070166802A1 (en) 2007-07-19
CN1935258B (zh) 2013-04-03
HRP20040195A2 (en) 2004-08-31
CN1273189C (zh) 2006-09-06
FR14C0016I1 (hu) 2014-03-28
HUP0401606A2 (hu) 2004-11-29
US20070166325A1 (en) 2007-07-19

Similar Documents

Publication Publication Date Title
HUS1300055I1 (hu) West Nile vakcina
IL227966A0 (en) Vaccination kit
GB0103170D0 (en) Vaccine composition
GB0103171D0 (en) Vaccine composition
GB0130215D0 (en) Vaccine
HUP0402259A3 (en) Vaccines
GB0407935D0 (en) Vaccine
IL157498A0 (en) Vaccine
EP1423141A4 (en) VACCINE
GB0306611D0 (en) Novel vaccine
GB0121171D0 (en) Vaccine
HK1219412A1 (zh) 對抗尼羅熱病毒的疫苗
GB0105238D0 (en) Vaccines
GB0128312D0 (en) Vaccine
GB0130823D0 (en) Vaccine
GB0124137D0 (en) Vaccine
GB0103867D0 (en) Vaccine
GB0115496D0 (en) Vaccine
GB0106589D0 (en) Vaccine
GB0107511D0 (en) Novel vaccine
GB0104542D0 (en) Novel vaccine
GB0104538D0 (en) Novel Vaccine
GB0113552D0 (en) Vaccines
GB0129338D0 (en) Vaccination
GB0101138D0 (en) Vaccine composition